Combining targeted agents with checkpoint inhibitors in cutaneous T-cell lymphoma

Both targeted agents, such as brentuximab vedotin, and checkpoint inhibitors, such as pembrolizumab, have shown activity in a subset of patients with cutaneous T-cell lymphoma. Francine Foss, MD at the Yale University, New Haven, CT is using this disease as a model to assess the efficacy and mechanism of action of combining targeted agents with checkpoint inhibitors.
Recorded at the International Workshop of Non-Hodgkin Lymphoma (iwNHL) 2017 meeting, held in Vancouver, BC, Canada.

• Kategorie